Fusion Pharmaceuticals Inc.

Fusion Pharmaceuticals Inc. is a clinical-stage oncology enterprise focused on creating precise radiopharmaceutical therapies. The company utilizes its groundbreaking Targeted Alpha Therapies platform, which incorporates its exclusive Fast-Clear linker technology. This innovative system enables the attachment of alpha particle-emitting isotopes to diverse targeting molecules, facilitating the targeted delivery of these potent payloads directly to cancerous growths. Its leading investigational compound, FPI-1434, is currently progressing through Phase 1 clinical trials as a singular treatment for individuals suffering from solid tumors that express the insulin-like growth factor 1 receptor. Beyond this, Fusion is conducting preclinical research into FPI-1434's effectiveness in conjunction with existing checkpoint inhibitors and DNA damage response inhibitors. These studies aim to thoroughly evaluate its anti-tumor effects, ideal dosage regimens, and pharmacological interactions within combination therapies. Furthermore, the firm is moving its earlier-stage candidate, FPI-1966, into clinical evaluation for the management of head and neck, and bladder cancers exhibiting fibroblast growth factor receptor. Fusion Pharmaceuticals also maintains a strategic partnership with AstraZeneca UK Limited, collaborating on the identification, advancement, and market introduction of alpha-emitting radiopharmaceuticals and combined cancer treatments. The company, established in 2014, is headquartered in Hamilton, Canada.